Protein kinase inhibitors

Details Protein kinase inhibitors Protein kinase inhibitors

2007-02-06

2007-02-06

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S262000

Reexamination Certificate

active

11178736

ABSTRACT:
Disclosed are compounds which inhibit or modulate the activity of protein kinases and pharmaceutical compositions containing such compounds. The disclosed compound contain two or more ligand moieties covalently linked together by one or more linking groups. Such compounds are useful for treating diseases or medical disorders mediated by protein kinases.

REFERENCES:
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5461146 (1995-10-01), Lewis et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5593991 (1997-01-01), Adams et al.
patent: 5593992 (1997-01-01), Adams et al.
patent: 5670527 (1997-09-01), Adams et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 5977103 (1999-11-01), Adams et al.
patent: WO 94/26260 (1994-11-01), None
patent: WO 96/21452 (1996-07-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 96/34867 (1996-11-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 97/40019 (1997-10-01), None
patent: WO 98/18782 (1998-05-01), None
patent: WO 98/37881 (1998-09-01), None
patent: WO 99/24442 (1999-05-01), None
patent: WO 00/61578 (2000-10-01), None
Adams et al., “Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases”, Current Opinion in Drug Discovery & Development, vol. 2(2), pp. 96-109 (1999).
Ayyangar et al., “Anthraquinone and Anthrone Series-XXIII/The Non-Identity of 1:3:8-Trihydroxy-2-Hydroxymethyl-Anthraquinone with Versicolorin and a Synthesis of Damnacanthol and Damnacanthal”, Tetrahedron , vol. 6, pp. 331-337 (1959).
Bajaj et al., Improved Preparative Synthesis of Piceatannol (3,4,3′,5′-Tetrahydroxy-Trans-Stilbene), Rev. Latinoamer Quim., vol. 18(2), pp. 79-80 (1987).
Bit et al., “Inhibitors of Protein Kinase C. 3. Potent and Highly Selective Bisindolylmaleimides by Conformational Restriction”, J. Med. Chem., vol. 36, pp. 21-29 (1993).
Bullington et al., “The Development of Novel and Selective p561ckTyrosine Kinse Inhibitors”, Bioorganic & Medicinal Chemistry Letters 8, pp. 2489-2494 (1998).
Bunin et al., “[26] Synthesis and Evaluation of 1,4-Benzodiazepine Libraries”, Methods in Enzymology, vol. 267, pp. 448-465 (1996).
Connolly et al., “Discovery and Structure-Activity Studies of a Novel Series of Pyrido[2,3-d]Pyrimidine Tyrosine Kinase Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 18, pp. 2415-2420 (1997).
Duncia et al., “MEK Inhibitors:The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2839-2844 (1998).
Faltynek et al., “Damnacanthal Is a Highly Potent, Selective Inhibitor of p561ckTyrosine Kinase Activity”, Biochemistry, vol. 34, pp. 12404-12410 (1995).
Fry et al., “Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor”, Proc. Natl. Acad. Sci, USA, vol. 95, pp. 12022-12027 (1998).
Furet et al., “Structure-Based Design, Synthesis, and X-ray Crystallography of a High-Affinity Antagonist of the Grb2-SH2 Domain Containing an Asparagine Mimetic”, J. Med. Chem., vol. 42, pp. 2358-2363 (1999).
Hamby et al., “Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors”, J. Med. Chem. vol. 40, pp. 2296-2303 (1997).
Hanefeld et al., “One-pot synthesis of tetrasubstituted pyrazoles-proof of regiochemistry”, J. Chem. Soc., Perkin Trans. 1, pp. 1545-1552 (1996).
Hanke et al., “Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor”, The Journal of Biological Chemistry, vol. 271, No. 2, Issue of Jan. 12, pp. 695-701 (1996).
Henry et al., “Potent Inhibitors of the Map Kinase p38”, Bioorganic & Medicinal Chemistry Letters 8, pp. 3335-3340 (1998).
Henry et al., “6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354):A Potent and Selective p38 Kinase Inhibitor”, J. Med. Chem., vol. 41, pp. 4196-4198 (1998).
Klutchko et al., “2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity”, J. Med. Chem, vol. 41, pp. 3276-3292 (1998).
Lawrence et al., “Protein Kinase Inhibitors: The Tyrosine-Specific Protein Kinases”, Pharmacol. Ther., vol. 77, No. 2, pp. 81-114 (1998).
Levitzki et al., “Tyrosine Kinase Inhibition:An Approach to Drug Development”, Science, vol. 267, pp. 1782-1788 (1995).
Maly et al., “Combinatorial target-guided ligand assembly:Identification of potent subtype-selective c-Src inhibitors”, PNAS, vol. 97, No. 6, pp. 2419-2424 (2000).
Myers et al., “The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiophenoxy)-Quinazolines: Inhibitors of p561ckand EGF-R Tyrosine Kinase Activity.”, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 4, pp. 417-420 (1997).
Profit et al., “Bivalent Inhibitors of Protein Tyrosine Kinases”, J. Am. Chem. Soc., vol. 121, pp. 280-283 (1999).
Ramdas et al., “Benzodiazepine Compounds as Inhibitors of the Src Protein Tyrosine Kinase: Screening of a Combinatorial Library of 1,4-Benzodiazepines”, Archives of Biochemistry and Biophysics, vol. 368, No. 2, pp. 394-400 (1999).
Schoepfer et al., “Highly Potent Inhibitors of the Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 221-226 (1999).
Shibuya et al., “Syntheses of Two Pairs of Enantiomeric C18-Sphingosines and a Palmitoyl Analogue of Gaucher Spleen Glucocerebroside”, Chem. Pham. Bull., vol. 40(5), pp. 1154-1165 (1992).
Smyth et al., “Non-Amine Based Analogues of Lavendustin A as Protein-Tyrosine Kinase Inhibitors”, J. Med. Chem., vol. 36, pp. 3010-3014 (1993).
Stover et al, “Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis”, Current Opinion in Drug Discovery & Development, vol. 2(4), pp. 274-285 (1999).
Sun et al., “Synthesis and Biological Evaluation of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases”, J. Med. Chem., vol. 41, pp. 2588-2603 (1998).
Tamaoki et al., “Staurosporine, A Potent Inhibitor of Phospholipid/Ca++ Dependent Protein Kinase”, Biochemical and Biophysical Research Communications, vol. 135, No. 2, pp. 397-402 (1986).
Trumpp-Kallmeyer et al., “Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors”, J. Med. Chem., vol. 41, pp. 1752-1763 (1998).
Vu et al., “Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70”, J. Med. Chem., vol. 42, pp. 4088-4098 (1999).
Williams et al., “Ro 09-2210 Exhibits Potent Anti-proliferative Effects on Activated T Cells by Selectively Blocking MKK Activity”, Biochemistry, vol. 37, pp. 9579-9585 (1998).
Yao et al., “Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands”, J. Med. Chem., vol. 42, pp. 25-35 (1999).
Zimmermann et al., Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC), Arch. Pharm. Pharm. Med. Chem., vol. 329, pp. 371-376 (1996).

Affiliated with

Also associated with

Rating

Protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3817601